Market Spotlight: Multiple Sclerosis Forecast

DISEASE OVERVIEW

Multiple sclerosis (MS) is an inflammatory, autoimmune disease characterized by neuronal demyelination leading to physical and cognitive disability. Although the etiology of MS is uncertain, it is thought to involve genetic, environmental, and infectious disease components. Current therapies for MS largely fall into two categories: symptomatic and disease-modifying, and both are frequently used in combination with one another.

MARKET SNAPSHOT

Ocrevus’s peak sales estimate increases as early data suggest it is competing across a range of treatment settings.
Despite the approvals of newer, more efficacious therapies, Copaxone and interferon beta remain key components of treatment practices in MS.
An overall increase in diagnosed prevalent MS cases is expected, despite declines in markets experiencing negative population growth.
Exciting newcomer Ocrevus is gaining considerable traction in only its first year of commercial availability.
Celgene must balance ozanimod pricing to maximize MS opportunity while ensuring reimbursement in secondary indications.
Products targeting progressive disease types will have favorable reimbursement.

Exclusive Sample Report @ https://www.reportsworldwide.com/enquiry?report_id=42618

CONTENTS

FORECAST: MULTIPLE SCLEROSIS (Published on 24 November 2017)
EXECUTIVE SUMMARY
RECENT FORECAST UPDATES
MARKET DYNAMICS
FORECAST AND FUTURE TRENDS
MARKET DEFINITION AND METHODOLOGY
PRIMARY RESEARCH METHODOLOGY
BIBLIOGRAPHY
PRODUCT PROFILE (LATE STAGE): ALKS 8700
PRODUCT PROFILE: AUBAGIO
PRODUCT PROFILE: AVONEX
PRODUCT PROFILE: BETASERON
PRODUCT PROFILE: COPAXONE
PRODUCT PROFILE: GILENYA
PRODUCT PROFILE: LEMTRADA

CONTINUED……………………………

LIST OF FIGURES
Figure 1: Multiple sclerosis – current and future market dynamics analysis
Figure 2: Datamonitor Healthcare’s assessment summary of key marketed and pipeline drugs for multiple sclerosis
Figure 3: Multiple sclerosis market sales across the US, Japan, and five major EU markets, by country, 2016–25
Figure 4: Growth dynamics of the multiple sclerosis market across the US, Japan, and five major EU markets, by country, 2016–25
Figure 5: Multiple sclerosis market sales across the US, Japan, and five major EU markets, by disease subtype, 2016–25
Figure 6: Methodology flow for Datamonitor Healthcare’s multiple sclerosis forecast
Figure 7: Price sources and calculations, by country
Figure 8: ALKS 8700 for multiple sclerosis – SWOT analysis

CONTINUED……………………………

LIST OF TABLES
Table 1: Multiple sclerosis market sales across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 2: Multiple sclerosis market sales across the US, Japan, and five major EU markets, by formulation ($m), 2016–25
Table 3: Multiple sclerosis market sales across the US, Japan, and five major EU markets, by disease subtype ($m), 2016–25
Table 4: Multiple sclerosis market treated patient numbers across the US, Japan, and five major EU markets, by disease subtype, 2016–25
Table 5: Sales of the top three highest selling drugs in multiple sclerosis in 2025 across the US, Japan, and five major EU markets ($m), 2016–25
Table 6: Summary of drug classes and molecules included in Datamonitor Healthcare’s multiple sclerosis patient-based forecast
Table 7: Exchange rates used for calculating prices
Table 8: Neurologists surveyed for the multiple sclerosis primary research study, 2016
Table 9: ALKS 8700 drug profile
Table 10: ALKS 8700 Phase III trials in multiple sclerosis

CONTINUED……………………………

Ask to Expertise @ https://www.reportsworldwide.com/enquiry?report_id=42618

About US:

Reportsworldwide.com is a one stop shop for all market intelligence needs. Our database of market research reports provides in depth coverage of 12 top industry verticals worldwide. We help you meet your market intelligence needs by mapping it with our database of market research reports including.

Contact Us:

Email: sales@reportsworldwide.com

Phone: +1 (617) 398-1947